OLE_NEATEryDex for Ataxia Telangiectasia Patients

This clinical study is designed to continue providing a treatment called EryDex to patients with a condition known as Ataxia Telangiectasia, who have already participated in an earlier study. Ataxia Telangiectasia is a rare genetic disorder affecting movement and immune system function. The main aim is to observe how patients respond to the treatment over a longer period. This study is important because it offers continuous treatment to those who have already been involved in previous research, potentially providing further insights into the effectiveness and safety of EryDex for managing symptoms of this challenging condition. Participants in this study will receive the EryDex treatment for 12 months. EryDex involves a special process where a medication called dexamethasone sodium phosphate is delivered inside the patient’s own red blood cells. This is done to help manage the symptoms of Ataxia Telangiectasia. Throughout the study, researchers will closely monitor the participants to ensure there are no safety issues and to gather more information on the treatment's impact on their health. By the end of the study, each participant will undergo a final safety check to complete their involvement.